Key Financial Performance - Standalone (Q1 FY27 vs Q1 FY26)
- Revenue from Operations: ₹4230.94 lakhs (up 45.01% from ₹2917.64 lakhs)
- EBITDA: ₹501.14 lakhs (up 21.32% from ₹413.06 lakhs)
- Other Income: ₹41.85 lakhs (down 45.89% from ₹77.34 lakhs)
- Finance Cost: ₹100.82 lakhs (up 18.42% from ₹85.14 lakhs)
- Depreciation and amortization: ₹200.96 lakhs (down 4.84% from ₹211.18 lakhs)
- Net Profit after tax: ₹210.03 lakhs (up 159.06% from ₹81.07 lakhs)
- Net Total Income: ₹4272.79 lakhs (up 42.67%)
- EBITDA Margin: 11.84% (compared to 14.16% in Q1 FY26)
Key Financial Performance - Consolidated (Q1 FY27 vs Q1 FY26)
- Revenue from Operations: ₹4230.94 lakhs (up 28.11% from ₹3302.54 lakhs)
- EBITDA: ₹496.57 lakhs (up 15.02% from ₹431.73 lakhs)
- Other Income: ₹41.85 lakhs (down 33.67% from ₹63.09 lakhs)
- Finance Cost: ₹100.81 lakhs (up 18.07% from ₹85.38 lakhs)
- Depreciation and amortization: ₹200.96 lakhs (down 4.84% from ₹211.18 lakhs)
- Net Profit after tax: ₹204.66 lakhs (up 105.44% from ₹99.62 lakhs)
- Net Total Income: ₹4272.79 lakhs (up 26.95% from ₹3365.63 lakhs)
- EBITDA Margin: 11.74% (compared to 13.07% in Q1 FY26)
Revenue Breakdown - Q1 FY27 (Consolidated)
Domestic Sales: ₹2652.11 lakhs (up 15.91% from ₹2288.17 lakhs)
- Branded Formulation: ₹737.67 lakhs (up 62.27% from ₹454.58 lakhs)
- Branded Veterinary: ₹587.35 lakhs (up 97.83% from ₹296.90 lakhs)
- P2P: ₹1327.09 lakhs (down 13.64% from ₹1536.69 lakhs)
Export Sales: ₹1483.42 lakhs (up 68.03% from ₹882.85 lakhs)
- Branded Formulation: ₹1483.42 lakhs (up 68.03% from ₹882.85 lakhs)
Other Operating Income: ₹95.41 lakhs (down 27.46% from ₹131.52 lakhs)
Company Business Description
Lyka Labs Limited is engaged in manufacturing and marketing of finished formulations for human and animal healthcare across various therapeutic segments.